Investigation of the role of i1- and i2-imidazoline receptors in the mechanіsm of the hypoglycemic action of n,n’-(ethane-1,2 dyyil)bis(quinoline- 2-carboxamide)
Keywords:N, N’-(ethane-1, 2-dyyil)bis(quinoline-2-carboxamide), hypoglycemic effect, imidazoline receptors, diabetes mellitus, 2-(4, 5-dihydroimidazol-2-yl)quinoline hydrochloride (BU 224), efaroxan, alloxan
The results of the investigation of the hypoglycemic action mechanism of N,N’-(ethane-1,2-dyyil)bis (quinoline-2-carboxamide) are presented. The substance was administered intragastrically in the dose of 11.64 mg/kg on the model of alloxan-induced diabetes mellitus in rats. It should be noted that the test compound in terms of the theory of pharmacophore can be considered as a dimer BU 224, but it is not its dimer in terms of organic chemistry. The information about the influence of the test compound on carbohydrate metabolism is limited. There are data that this compound has antitumor properties іn vitro due to enhanced apoptosis and activation of caspase-3. Proceeding from the chemical structure, the 2-substituted quinoline fragment is present in the structure of the known antagonist of imidazoline receptors I2 such as 2-(4,5-dihydroimidazol-2-yl)quinoline hydrochloride, so it can be assumed that N,N’-(ethane-1,2-dyyil)bis(quinoline-2-carboxamide) has the ability to interfere with the mechanisms of the carbohydrate metabolism regulation. These results indicate that N,N’-(ethane- 1,2-dyyil)bis(quinolin-2-carboxamide) has an expressed hypoglycemic effect in alloxan-induced diabetes mellitus reducing the blood glucose level by 71.50%. It is an agonist of imidazoline receptors of both types, and it has been proven by blockade with selective antagonists such as efaroxan and 2-(4,5-dihydroimidazol-2-yl)quinoline hydrochloride. On the background of I1-imidazoline receptors blocker efaroxan the glycemia decrease was 45.66% (p<0.05), and on the background of I2-imidazoline receptors blocker 2-(4,5-dihydroimidazol-2-yl)quinoline hydrochloride it was 54.01% (p<0.05).
Балаболкин М.И. Диабетология. – М.: Медицина, 2000. – 471 с.
Козаева Л.П., Коробов Н.В., Медведев О.С. // Эксперимент. и клин. фармакол. – 2003. – Т. 66, №5. – С. 69-73.
Миронов А.Н. Руководство по проведению доклинических исследований лекарственных средств. – М.: Гриф и К, 2012. – Ч. I. – 944 с.
Стефанова О.В. Доклінічні дослідження лікарських засобів: Метод. рекоменд. – К.: Авіценна, 2001. – 400 с.
American Diabetes Association // Diabetes Care. – 2006. – Vol. 29. – P. 1-42.
Cheng C.H., Tsao C.W., Huang S.Y. et al. // Neorosci. Lett. – 2009. – Vol. 467. – Р. 147-149.
Cheng J.T., Huang C.C., Liu I.M. et al. // Diabetes. – 2006. – Vol. 55. – P. 819-825.
Dave K.R., Katyare S.S. // J. оf Endocrinol. – 2002. – Vol. 175, №1. – Р. 241-250.
Echeverria M., Mendivil B., Cordeuetal L. // Arch. Pharm. Chem. Life Sci. – 2006. – Vol. 339. – P. 182-192.
Ernsberger P. // Ann. NY Acad. Sci. – 1999. – Vol. 881. – P. 35-53.
Harron D. // N. Fundam. Clin. Pharmacol. – 1992. – Vol. 6. – P. 41-44.
Huang S., Zhong R., Liang M. // China J. Mod. Med. – 2004. – Vol. 14, №17. – P. 34-36.
Kalapko O.N., Shtrygol’ S.Yu. // The XXI Intern. Sci. and Pract. Conf. of young Scientists and students “Actual questions of development of new drugs” April 22, 2014, Kharkiv.
Kekalainen P., Sarlund H., Pyorala K. // Diabetes Care. – 1999. – Vol. 22, №1. – P. 86-92.
Lebovitz H.Е., Austin M.M., Blonde L. et al. // Endocrin. Pract. – 2006. – Vol. 12 (Suppl. 1). – P. 6-12.
Lee J.P., Chen W., Wu H.T. et al. // Horm. Metab. Res. – 2011. – Vol. 43, №1. – P. 26-30.
Ong K.L., Cheung B.M., Wong L.Y. et al. // Ann. Epidemiol. – 2009. – Vol. 18. – P. 222-229.
Copyright (c) 2014 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).